Timber Pharmaceuticals’ candidate for rare skin disorder flunks all endpoints in late-stage trial

Dermatology biotech Timber Pharmaceuticals’ Phase 3 trial investigating its treatment in a rare inherited skin disorder missed all primary and secondary endpoints, the company announced …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

How Effective Are the Latest COVID Shots?

The 24-hour news cycle is just as important to medicine as it is to politics, finance, or sports. At MedPage Today, new information is posted

February 4, 2024

argenx’s VYVDURA gains approval in Japan for gMG treatment

Share this article argenx’s VYVDURA SC injection is indicated to treat generalised myasthenia gravis patients who have inadequate response to steroids or non-steroidal ISTs. Credit:

January 19, 2024

Tang Capital continues biotech buying spree with acquisition bid for Rain Oncology

California investment group Tang Capital Management has made its third takeover bid of the year for a struggling biotech, this time aimed at US company

October 17, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.